Bulletin Du Cancer最新文献

{"title":"Réflexions sur l’innovation thérapeutique en oncologie","authors":"Dominique Levêque","doi":"10.1016/j.bulcan.2025.04.012","DOIUrl":"10.1016/j.bulcan.2025.04.012","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1082-1086"},"PeriodicalIF":0.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ototoxicité radio-induite au cours du traitement des tumeurs des voies aéro-digestives supérieures et de la base du crâne","authors":"Rafik Nebbache ,&nbsp;Florence Huguet ,&nbsp;Juliette Thariat ,&nbsp;Charles Maquet ,&nbsp;Fabrice Giraudet ,&nbsp;François-Régis Ferrand","doi":"10.1016/j.bulcan.2025.06.007","DOIUrl":"10.1016/j.bulcan.2025.06.007","url":null,"abstract":"<div><div>La radiothérapie, combinée ou non au cisplatine, constitue un pilier du traitement des cancers ORL et de la base du crâne. Cependant, elle expose à une ototoxicité significative, touchant la cochlée et l’appareil vestibulaire, avec des répercussions majeures sur l’audition, l’équilibre et la qualité de vie. Les patients peuvent développer des surdités, des acouphènes ou des troubles vestibulaires parfois invalidants. Cette toxicité repose sur des mécanismes complexes incluant des dommages directs aux cellules sensorielles, une ischémie locale et des réponses inflammatoires, conduisant à une dégradation progressive des fonctions auditives et vestibulaires. Malgré les avancées techniques, comme la radiothérapie conformationnelle avec modulation d’intensité (RCMI), permettant de limiter les doses reçues par les structures auditives, ces effets secondaires restent fréquents. Un suivi audiométrique rigoureux et l’optimisation des stratégies thérapeutiques sont essentiels pour en limiter l’impact. L’ototoxicité radio-induite demeure un défi majeur en oncologie ORL, nécessitant une prise en charge multidisciplinaire pour préserver la qualité de vie des patients.</div></div><div><div>Radiotherapy, with or without cisplatin, is a cornerstone in the treatment of head and neck cancers and skull base tumors. However, it poses a significant risk of ototoxicity, affecting the cochlea and vestibular apparatus, with major repercussions on hearing, balance, and overall quality of life. Patients may experience hearing loss, tinnitus, or vestibular disorders that can be debilitating. This toxicity stems from complex mechanisms, including direct damage to sensory cells, local ischemia, and inflammatory responses, leading to a progressive decline in auditory and vestibular functions. Despite technical advances such as intensity-modulated radiotherapy (IMRT), which helps limit doses to auditory structures, these side effects remain common. Rigorous audiometric monitoring and optimization of therapeutic protocols are essential to mitigate their impact. Radiation-induced ototoxicity remains a major challenge in head and neck oncology, requiring a multidisciplinary approach to preserve patients’ quality of life.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1172-1182"},"PeriodicalIF":0.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of a National French Survey on use of KELIM model for management of patients with advanced stage epithelial ovarian cancer (SFOG Campus)","authors":"Diana Bello Roufai ,&nbsp;Houssein El Hajj ,&nbsp;Phuong Lien Tran ,&nbsp;Pierre Descargues ,&nbsp;Guillaume Babin ,&nbsp;Sarah Betrian Lagarde ,&nbsp;Benoît You ,&nbsp;Elise Deluche","doi":"10.1016/j.bulcan.2025.04.007","DOIUrl":"10.1016/j.bulcan.2025.04.007","url":null,"abstract":"<div><h3>Purpose</h3><div>Ovarian cancer, predominantly epithelial, is the ninth most common and fifth most lethal cancer among women in France, with late diagnosis and poor prognosis despite curative treatments. The KELIM model, built according to Ca125 kinetics, given its proven predictive and prognostic characteristics, has been implemented online to aid therapeutic decision-making.</div></div><div><h3>Method</h3><div>This study assessed the use of the KELIM score among French gynecological oncology experts using a survey sent from 13 December 2023 to 30 January 2024, through Google forms to all member of French Society of Gynecological Oncology (SFOG), Young of French Society of Gynecological Oncology (SFOG campus) and National Investigators Group for Ovarian and Breast Cancer Studies in France (GINECO-ARCAGY).</div></div><div><h3>Results</h3><div>Fifty-two respondents, mainly gynecology and medical oncologists, revealed that 58% of them have used KELIM score, primarily in neoadjuvant settings. Participants considered that the KELIM score was mainly used to define the chemosensitivity (79%) and to identify patients who could then receive bevacizumab (82%). In the maintenance setting, the KELIM score was reported as quite frequently used (41%). It was inconsistently used to help the surgical procedure decision (37%).</div></div><div><h3>Conclusion</h3><div>The KELIM score predictive value for chemosensitivity, is acknowledged, especially for bevacizumab indications. However, its adoption into routine practice is dependent on the level of familiarity of practitioners. The findings suggest that while KELIM is seen as a potential useful tool for reinforcing therapeutic strategies, including choice of maintenance therapy or sequence of cytoreduction surgery, its broader adoption requires enhanced education and prospective validation.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1095-1102"},"PeriodicalIF":0.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La chirurgie tubaire prophylactique avant ovariectomie différée : éléments techniques à connaître","authors":"Delphine Hudry ,&nbsp;Carlos Martinez-Gomez ,&nbsp;Fabrice Narducci ,&nbsp;Camille Pasquesoone ,&nbsp;Eric Leblanc","doi":"10.1016/j.bulcan.2025.03.019","DOIUrl":"10.1016/j.bulcan.2025.03.019","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1225-1228"},"PeriodicalIF":0.8,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imagerie moléculaire et radio-ligands dans le cancer du sein","authors":"Mathilde Masse ,&nbsp;Caroline Bailleux ,&nbsp;Anne Creisson ,&nbsp;Olivier Humbert","doi":"10.1016/j.bulcan.2025.02.014","DOIUrl":"10.1016/j.bulcan.2025.02.014","url":null,"abstract":"<div><div>L’imagerie moléculaire joue un rôle crucial dans le diagnostic, la stadification et le suivi du cancer du sein. Le traceur le plus couramment utilisé à l’heure actuelle est le 18F-FDG, traceur du métabolisme cellulaire, faisant désormais de la TEP au 18F-FDG une imagerie majeure de la prise en charge des néoplasies mammaires. Néanmoins, ce traceur a ses limites, notamment pour les néoplasies lobulaires ou canalaires de bas grade, ayant une faible avidité pour le 18F-FDG. Le 68Ga-FAPI, traceur des fibroblastes activés dont la fixation ne dépend pas de l’agressivité de la tumeur, actuellement utilisé en recherche, pourrait présenter une excellente alternative au 18F-FDG dans certaines situations. De plus, de nouveaux traceurs se développent, ciblant les voies biologiques de la tumeur, notamment les récepteurs hormonaux ou HER2, permettant ainsi d’analyser l’expression de biomarqueurs spécifiques sur les cellules cancéreuses à l’échelle du corps entier et offrant une vision plus spécifique de la maladie. Elle pourrait contribuer à personnaliser les traitements en fonction des caractéristiques moléculaires spécifiques de chaque tumeur permettant une approche personnalisée, améliorant l’efficacité thérapeutique et la qualité de vie des patients. Enfin, sur le modèle du 177Lu-PSMA utilisé pour le cancer de la prostate, des auteurs s’intéressent à la possibilité de coupler ces traceurs à un agent thérapeutique afin de développer la radiothérapie interne vectorisée des néoplasies mammaires.</div></div><div><div>Molecular imaging plays a crucial role in the diagnosis, staging, and monitoring of breast cancer. The most commonly used tracer at present is 18F-FDG, a marker of cellular metabolism, making 18F-FDG PET/CT a major imaging modality in the management of breast neoplasms. However, this tracer has limitations, particularly for low-grade ductal or lobular neoplasms, which exhibit low avidity for 18F-FDG. The 68Ga-FAPI tracer, which targets activated fibroblasts and whose uptake is independent of tumor aggressiveness, is currently under investigation and could serve as an excellent alternative to 18F-FDG in certain cases. Additionally, new tracers targeting novel biological pathways of the tumor, including hormonal receptors or HER2, are being developed. These tracers enable whole-body assessment of specific biomarker expressions on cancer cells, offering a more precise understanding of the disease. This approach could help tailor treatments to the molecular characteristics of each tumor, enabling personalized strategies that improve therapeutic efficacy and patient quality of life. Finally, inspired by the model of 177Lu-PSMA used in prostate cancer, researchers are exploring the potential to couple these tracers with therapeutic agents to develop targeted radionuclide therapy for breast neoplasms.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 702-713"},"PeriodicalIF":0.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib en traitement d’entretien après radiochimiothérapie dans les cancers bronchiques non à petites cellules localement avancés avec délétion de l’exon 19 ou mutation L858R de l’exon 21 de l’EGFR","authors":"Lisa Bosquain ,&nbsp;Olivier Bylicki","doi":"10.1016/j.bulcan.2025.03.015","DOIUrl":"10.1016/j.bulcan.2025.03.015","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 693-694"},"PeriodicalIF":0.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Formes familiales de cancer du sein – dépistage génétique et surveillance en fonction du risque","authors":"Jessica Moretta ,&nbsp;Dorine Livon ,&nbsp;Catherine Noguès","doi":"10.1016/j.bulcan.2025.04.005","DOIUrl":"10.1016/j.bulcan.2025.04.005","url":null,"abstract":"<div><div>L’identification des femmes selon leur niveau de risque de cancer du sein est essentielle puisque leur prise en charge, en termes de dépistage et de prévention peut ainsi être adaptée. La consultation d’oncogénétique vise à étudier l’histoire personnelle et familiale de cancers afin d’identifier les situations évocatrices d’une prédisposition héréditaire et proposer des analyses génétiques. Une liste de treize gènes à analyser en cas de suspicion de risque héréditaire de cancer du sein ou des ovaires est établie en France depuis 2017. La mise en évidence d’un variant pathogène constitutionnel des gènes <em>BRCA1</em>, <em>BRCA2</em>, <em>PALB2</em>, <em>TP53</em>, <em>CDH1</em>, <em>PTEN</em> confère un niveau de risque de cancer du sein considéré comme « très élevé » chez les femmes porteuses. Elles se voient recommander une surveillance mammaire intensifiée. Un variant pathogène sur un gène d’intérêt est identifié dans moins de 10 % des familles testées. Lorsque l’analyse génétique est négative, l’évaluation faite par l’oncogénéticien permet de distinguer les familles où les femmes restent considérées à risque « élevé » de cancer du sein, de celles où les femmes sont à risque « très élevé » selon la terminologie du référentiel de la Haute Autorité de santé 2014. En outre, chez les personnes déjà affectées par un cancer, la connaissance de certaines données de génétique constitutionnelle est susceptible de conditionner la prise en charge thérapeutique. Ces considérations doivent intervenir dans le respect du cadre éthique spécifique compte tenu des enjeux psychosociaux et de santé, que représentent la connaissance d’un variant pathogène constitutionnel et l’éventualité de sa transmission héréditaire.</div></div><div><div>In France breast cancer is the most common cancer among women and the leading cause of cancer deaths. Identifying women with a “high” or “very high” breast cancer risk, according to the terminology of the Haute Autorité de santé 2014 guidelines, is essential to offer them special cares in term of screening and prevention. Women genetically predisposed have a very high risk of breast cancer. During the oncogenetic specialist consultation, familial and personal history of cancer is considered to evaluate the risk of hereditary Breast/Ovarian syndrome and thus the need of a genetic screening. In 2017 a list of 13 genes involved in hereditary ovarian or breast cancer has been established in France (Genetic and Cancer Group – Unicancer). Women carrying a <em>BRCA1</em>, <em>BRCA2</em>, <em>PALB2</em>, <em>TP53</em>, <em>CDH1</em>, <em>PTEN</em> mutation have a higher risk of breast cancer and are considered as “high risk”. Therefore medical breast surveillance similar to carriers of <em>BRCA1</em>/<em>BRCA2</em> mutation is recommended for these patients (INCa guidelines 2017). However a mutation in one of those genes is only identified in approximatively 10% of the screened families. The oncogenetic specialist's assessment","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 714-724"},"PeriodicalIF":0.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Professeur Maurice Schneider : un des pères fondateurs de la cancérologie française nous a quittés","authors":"Jérôme Barrière","doi":"10.1016/j.bulcan.2025.05.004","DOIUrl":"10.1016/j.bulcan.2025.05.004","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 921-922"},"PeriodicalIF":0.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Désescalade du traitement locorégional dans le cancer du sein","authors":"Gilles Houvenaeghel ,&nbsp;Catherine Bouteille ,&nbsp;Marc Martino ,&nbsp;Agnès Tallet ,&nbsp;Monique Cohen","doi":"10.1016/j.bulcan.2025.04.003","DOIUrl":"10.1016/j.bulcan.2025.04.003","url":null,"abstract":"<div><div>Le traitement locorégional des cancers du sein repose sur la chirurgie du sein et du creux axillaire, la radiothérapie du sein ou de la paroi thoracique et des aires ganglionnaires régionales. Une désescalade thérapeutique progressive a été réalisée afin de diminuer l’impact des traitements. Cette désescalade va être envisagée au niveau du traitement mammaire et au niveau ganglionnaire lors d’une prise en charge chirurgicale première et en cas de chimiothérapie néo-adjuvante.</div></div><div><div>Locoregional treatment of breast cancer is based on surgery of the breast and axilla, radiotherapy of the breast or chest wall and regional lymph node areas. A progressive therapeutic de-escalation was carried out in order to reduce the impact of the treatments. This de-escalation will be considered for breast treatment and for lymph node area during primary surgical treatment and for neo-adjuvant chemotherapy.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 789-797"},"PeriodicalIF":0.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spécificités de la prise en charge du cancer du sein chez les adolescents et jeunes adultes (AJA)","authors":"Florence Coussy ,&nbsp;Enora Laas ,&nbsp;Kim Cao ,&nbsp;Anne-Sophie Hamy ,&nbsp;Delphine Loirat ,&nbsp;Valerie Laurence","doi":"10.1016/j.bulcan.2025.04.004","DOIUrl":"10.1016/j.bulcan.2025.04.004","url":null,"abstract":"<div><div>Le cancer du sein chez les adolescents et jeunes adultes (AJA) est un événement rare mais qui nécessite une organisation maîtrisée et adaptée à cette population particulière. Les consultations d’oncogénétique et d’oncofertilité sont indispensables lors du diagnostic d’un cancer du sein chez une AJA. La prise charge thérapeutique suit les recommandations pour les cancers du sein, en portant une attention particulière aux risques d’effets secondaires à long terme, aux potentielles mutations génétiques constitutionnelles, et aux particularités concernant l’hormonothérapie. Le nombre de personnes adultes guéries d’un cancer dans l’enfance/AJA augmente chaque année. La morbidité liée aux traitements reçus et le risque de second cancer engendrent des besoins de soins et de suivi qu’il convient d’organiser, d’anticiper et d’adapter.</div></div><div><div>Breast cancer in adolescents and young adults (AYAs) is a rare event but requires a well-structured and tailored approach for this specific population. Oncogenetic and oncofertility consultations are essential at the time of breast cancer diagnosis in an AYA. Therapeutic management follows breast cancer guidelines, with particular attention to the risks of long-term side effects, potential constitutional genetic mutations, and specific considerations regarding hormone therapy. The number of adults who have survived cancer during childhood or adolescence/young adulthood increases each year. The morbidity associated with prior treatments and the risk of secondary cancers create needs for care and follow-up, which must be organized, anticipated, and adapted.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 853-859"},"PeriodicalIF":0.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}